ALKS earnings date and last-quarter result: last quarter miss, P/E 56.54. Updated 2026-07-23.
Alkermes (ALKS) Research Hub
Alkermes (ALKS) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 44.44 USD (+1.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 56.54, market cap 8.75B. This hub links to the full technical, earnings and options research available for ALKS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 44.44 USD (+1.86%) |
| 52-week range | 38.98 USD – 55.67 USD |
| Trend regime | Range |
| 14-day RSI | 62.4 (Bullish) |
| Trailing P/E | 56.54 |
| Market cap | 8.75B |
| Dividend yield | 0.00% |
Available research for ALKS
Covered Call on ALKS: how it works, illustrative setup around the real 44.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALKS: how it works, illustrative setup around the real 44.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALKS: how it works, illustrative setup around the real 44.44 USD price, max profit/loss, breakeven and when to use it. Educational.
ALKS technical analysis: range, last 44.44 USD, RSI 62.4, 52w range 38.98 USD–55.67 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ALKS in?
Alkermes (ALKS) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is ALKS in an uptrend or downtrend?
As of 2026-10-26, ALKS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALKS's trailing P/E ratio?
ALKS's trailing P/E is 56.54, with a market cap of 8.75B. See the earnings research page for full valuation detail.